昂利康(002940.SZ)擬收購科瑞生物61%股權 明起復牌
格隆匯4月12日丨 昂利康(002940.SZ)公佈,公司擬通過發行股份方式購買甘紅星等21名自然人合計持有的科瑞生物61%股權,並向不超過35名符合條件的特定投資者發行股份募集配套資金。此次交易包括髮行股份購買資產和募集配套資金兩部分。
截至預案簽署日,公司已持有科瑞生物23.48%股份,此次交易完成後,公司將持有科瑞生物84.47%股份,科瑞生物將成為公司的控股子公司。
截至預案簽署日,此次交易標的資產交易價格尚未確定,經交易各方協商確定,標的資產的交易價格不高於5.6億元,標的資產的最終交易價格將參考上市公司聘請的符合相關法律法規的資產評估機構出具的資產評估報吿載明的評估值,由交易各方協商確定。截至預案簽署日,此次交易標的公司的審計、評估工作尚未完成。此次交易中各交易對方獲得的股份數量將在標的公司審計、評估工作完成,標的資產的最終交易價格確定後,由交易各方協商確定,並在此次交易的重組報吿書中予以披露。
標的公司科瑞生物主要從事植物源膽固醇及其衍生產品維生素D系列、甾體藥物中間體的研發、生產和銷售,面向的終端客户主要為國內外大型醫藥企業。此次交易完成後,公司將置入盈利能力較強的優質資產。公司的醫藥業務將得到進一步拓展,主要產品範圍將新增植物源膽固醇及其衍生產品維生素D系列、甾體藥物中間體等,有助於增強上市公司的可持續發展能力和核心競爭力。
根據相關規定,經向深圳證券交易所申請,公司股票自2022年4月13日開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.